Amikacin (BB-K8) Treatment of Multiple-Drug-Resistant Proteus Infections

AUTOR(ES)

Sharp, Philip M.

RESUMO

The new aminoglycoside antibiotic, amikacin (formerly called BB-K8), was used to treat 12 episodes of urinary tract infection caused by hospital-acquired Proteus rettgeri strains. These bacteria were resistant in vitro to kanamycin and gentamicin, and infection persisted in most of the patients in spite of therapy with one of these agents. In all cases, the urinary tract infection was controlled or eradicated by therapy, although relapse or reinfection was frequently encountered in these patients with complicated urological problems. No toxicities attributable to the drug were encountered in the small group of patients.

Documentos Relacionados

• Rapid, Specific Microbiological Assay for Amikacin (BB-K8)
• Activity of BB-K8 (Amikacin) Against Clinical Isolates Resistant to One or More Aminoglycoside Antibiotics
• Salmonella Gene rma (ramA) and Multiple-Drug-Resistant Salmonella enterica Serovar Typhimurium
• Spoligotyping of Mycobacterium tuberculosis Isolates from Multiple-Drug-Resistant Tuberculosis Patients from Bombay, India
• Molecular Evidence for Heterogeneity of the Multiple-Drug-Resistant Mycobacterium tuberculosis Population in Scotland (1990 to 1997)